Sagimet beats estimates on lower burn, advances MASH combo therapy
Cash position of $113M provides runway as biotech prepares for Phase 2 F4 MASH trial in 2026
Sagimet Biosciences reported a narrower-than-expected quarterly loss and maintained a substantial cash position as the biotechnology company advances clinical trials for its fatty acid synthase inhibitor in metabolic disease and acne.
The company posted a fourth-quarter 2025 net loss of $9.6 million, an improvement from $16.2 million in the same period a year earlier. The loss per share of $0.29 beat analyst estimates by 26.4 percent, which had projected a loss of $0.39 per share. However, full-year losses widened to $51 million from $45.6 million in 2024.
Sagimet's cash, cash equivalents and marketable securities stood at approximately $113.1 million as of December 31, 2025, down from $158.6 million a year earlier. The position provides roughly two years of runway at the current burn rate, a critical metric for clinical-stage biotechnology companies.
The financial results come as Sagimet progresses its lead asset denifanstat through development, targeting metabolic dysfunction-associated steatohepatitis (MASH), a liver disease affecting millions of patients globally. The company recently completed a Phase 1 pharmacokinetic trial combining denifanstat with resmetirom, the active ingredient in Madrigal Pharmaceuticals' Rezdiffra, the first FDA-approved MASH treatment.
Sagimet plans to advance the combination into a Phase 2 proof-of-concept trial for patients with F4 fibrosis in the second half of 2026. The company also secured a global, exclusive license to TAPI's innovative forms of resmetirom for potential development of a fixed-dose combination product.
The MASH treatment market is projected to reach $6 billion by 2032, with a compound annual growth rate of 24.7 percent. Madrigal's Rezdiffra received FDA approval in March 2024, while Novo Nordisk has reported positive Phase 3 results for semaglutide in MASH patients and expects to file for regulatory approval in the first half of 2025.
Sagimet's strategy differs through its focus on inhibiting fatty acid synthase (FASN), an enzyme that plays a central role in fat metabolism. Secondary analysis from the company's FASCINATE-2 Phase 2b trial showed denifanstat led to significant fibrosis improvement in F3 MASH patients and improved biomarkers in qFibrosis stage 4 patients.
In acne treatment, Sagimet's partner Ascletis Bioscience reported positive topline results from an open-label Phase 3 trial of denifanstat tablets for moderate to severe acne in China. China's National Medical Products Administration accepted Ascletis' New Drug Application for the indication in December 2025. Sagimet initiated a Phase 1 trial of TVB-3567, another FASN inhibitor for acne, in June 2025.
Sagimet shares, which have traded between $1.73 and $11.41 over the past 52 weeks, recently changed hands at approximately $5.53. The company's market capitalization stands at roughly $176 million.
Analysts remain broadly optimistic about Sagimet's prospects. Eight analysts rate the stock a buy or strong buy, with one hold rating and no sell ratings. The consensus price target of $25.78 represents 367 percent upside from current levels. HC Wainwright & Co. has set the most bullish target at $32 per share.